Thomas J. Schuetz, MD, PhD has over 20 years of experience in oncology, biopharmaceutical drug development and life science venture investing. He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. As a physician-scientist and serial entrepreneur, he aspired to create an antibody therapeutic company based on novel biology, protein engineering, and key medical insights gathered throughout his career. While at OrbiMed, Thomas co-founded Audentes Therapeutics, now a publicly-traded biotechnology company where he remains a director. Also at OrbiMed, he was responsible for the investments in Enobia Pharma, Relypsa, and Arteaus Therapeutics, and served as a director at each of those companies. Enobia was acquired by Alexion Pharmaceuticals in 2011, Relypsa was acquired by Galencia in 2016, and Arteaus was acquired by Eli Lilly in 2014. Thomas has multiple years of clinical strategy, development, and operations experience, including roles as chief medical officer of Therion Biologics Corporation, a cancer vaccine company, and as vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.
Thomas completed his medical training at Massachusetts General Hospital, where he served as the chief medical resident. He completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Thomas holds a BS in chemistry from Xavier University, an MD from Harvard Medical School, and a PhD in genetics from Harvard University. Thomas is board certified in medical oncology.